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S U M M A R Y
Objective: To describe the clinical and microbiological features associated with fungal peritonitis in
peritoneal dialysis (PD) patients at Hoˆpital Maisonneuve-Rosemont, from August 1996 to July 2006.
Methods: Cases were retrieved from the microbiology laboratory culture registry. Antifungal
susceptibility was determined by the Clinical and Laboratory Standards Institute M27A3 method.
Results: Among 288 PD patients (total follow-up of 7258 patient-months), nine were found with fungal
peritonitis. Candida spp were identiﬁed in all of them, with a majority of non-albicans Candida species.
Resistance to ﬂuconazole, itraconazole, or voriconazole was as frequent as potential resistance to
amphotericin B. No isolate was resistant to caspofungin and one was resistant to micafungin. Prior
bacterial peritonitis was frequent (67%). All patients had their PD catheter removed and all of them
survived.
Conclusions: In our institution, fungal peritonitis in PD patients is rare. All cases were caused by Candida
species. Variable susceptibility patterns were observed, which may inﬂuence the initial empirical
antifungal therapy and underscore the importance of individual speciation and susceptibility testing of
invasive Candida isolates.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Fungal peritonitis (FP) is a rare but serious complication of
peritoneal dialysis (PD).1 It is associated with temporary and
frequently permanent cessation of PD. The lethality, although
variable, remains very high.2 The majority of these infections are
caused by Candida species. In recent reports, non-albicans
Candida species were more prevalent than Candida albicans in PD
patients with FP.2,3 These non-albicans Candida species, such as
Candida glabrata and Candida krusei, frequently exhibit resis-
tance to triazole antifungals. Only two studies on FP in PD
patients have reported antifungal susceptibility to triazoles4,5
and none have reported susceptibility to echinocandins. We
reviewed our 10-year experience with fungal peritonitis in
our PD population with an emphasis on in vitro susceptibility
of the isolates to different antifungal antibiotics, including
echinocandins.* Corresponding author. Tel.: +1 514 252 3489; fax: +1 514 255 3026.
E-mail address: mvallee.hmr@ssss.gouv.qc.ca (M. Valle´e).
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Hoˆpital Maisonneuve-Rosemont is a tertiary-care university
hospital. Its PD population lives in an urban environment located in
the eastern part of Montreal (Canada). All FP cases were retrieved
through a systematic review of all peritoneal ﬂuid cultures sent to
our microbiology laboratory from August 1996 to July 2006. During
this 10-year period, 288 adult patients were treated by PD in our
hospital, for a total experience of 7258 patient-months. During the
same period, 289 episodes of peritonitis were recorded for a global
incidence of 1 episode per 25 patient-months (0.48 episodes per
patient-year). The diagnosis of peritonitis was based on the positivity
of two out of three criteria: abdominal pain, peritoneal ﬂuid cell
count of >0.1 leukocytes/l, or positive peritoneal ﬂuid culture. The
medical records of all PD patients with a peritoneal ﬂuid culture
positive for a fungus were reviewed for demographics, duration of
prior experience with PD, presence of potential risk factors for FP
(diabetes, immunosuppressive therapy, recent antibacterial therapy,
recent episode of bacterial peritonitis, or bowel perforation),
conﬁrmation of a peritonitis episode, nature and duration of the
antifungal therapy, and evolution (days of hospitalization, survival,
catheter removal, delay between diagnosis of FP and catheter
removal, and deﬁnitive or temporary transfer to hemodialysis).ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Antifungal susceptibility of nine cases of fungal peritonitis (minimum inhibitory concentrations in mg/l)
Year Sex/age Species Amphotericin B Fluconazole Itraconazole Voriconazole Caspofungin Micafungin
1997 F/56 C. tropicalis 0.25 0.5 0.12 0.03 0.03 0.25
1997 M/78 C. parapsilosis 0.5 1 0.12 0.016 1 16 R
1997 M/35 C. tropicalis 0.25 0.5 0.25 0.06 0.12 0.5
1997 M/75 C. albicans 0.5 1 0.12 0.12 0.12 0.25
1998 M/69 C. parapsilosis 0.125 2 0.06 0.008 0.25 2
1999 M/67 C. krusei 1 Ra 0.5 0.5 1 2
2001 F/62 C. parapsilosis 2 R 0.25 0.06 0.016 0.5 0.06
2002 M/51 C. glabrata 2 R 16 I 32 R 32 R 0.5 0.06
2003 M/61 C. tropicalis 2 R 4 1 R 0.5 1 0.25
R, resistant; I, intermediate.
a C. krusei are assumed to be intrinsically resistant to ﬂuconazole.
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isolates were performed with germ tubes, chlamydospore forma-
tion, Vitek YBC identiﬁcation system (BioMe´rieux, St-Laurent, Qc,
Canada), and the Clinical and Laboratory Standards Institute (CLSI)
broth microdilution susceptibility testing method.6 Standard
antifungal powders were used: amphotericin B, itraconazole
(Ortho-Janssen), ﬂuconazole, voriconazole (Pﬁzer), micafungin
(Astellas-Pharma), and caspofungin (Merck). Serial two-fold
dilutions were made in RPMI 1640 medium (Gibco BRL) buffered
to pH 7.0 with 0.165 3N-morpholino-propanesulfonic acid (MOPS)
buffer (Sigma) for all antibiotics. The ﬁnal concentrations of the
antifungal agents were: 0.008 to 16 mg/l for amphotericin B,
itraconazole, voriconazole, micafungin, and caspofungin, and 0.25
to 256 mg/l for ﬂuconazole. Drug-free and yeasts-free controls
were included. Trays were incubated in air at 35 8C, and minimum
inhibitory concentration (MIC) endpoints were visually read after
48 h of incubation. The MICs of amphotericin B were deﬁned as the
lowest concentration resulting in a complete inhibition of growth,
while the MICs of all the other compounds were deﬁned as the
lowest concentration that resulted in a substantial reduction of
growth (80% inhibition) compared to that of growth-control wells.
Candida parapsilosis ATCC 22019 and C. krusei ATCC 6258 reference
strains were used for quality control. In vitro susceptibilities were
evaluated according to the currently established interpretation
criteria of the CLSI. For ﬂuconazole, strains are considered
susceptible when the MIC is 8 mg/l, intermediate when the
MIC is 16–32 mg/l, and resistant when the MIC is 64 mg/l.
Corresponding criteria for itraconazole are 0.125, 0.25–0.5, and
1 mg/l. Resistance to voriconazole was deﬁned as a MIC 4 mg/l.
Non-susceptibility to echinocandins was deﬁned as a MIC >2 mg/l.
Since no established criteria exist for amphotericin B, strains with
values >1 mg/l were considered resistant, as proposed by the CLSI.
3. Results
Between August 1996 and July 2006, among 288 patients on PD,
nine cases of FP were identiﬁed in nine patients (seven men and
two women) during their PD follow-up. The incidence of FP was 1
episode per 806 patient-months (1 episode per 67 patient-years),
representing 3.1% of all peritonitis episodes that occurred in our PD
population during the same period. The mean patient age was 62
years (range 35–78 years). Three patients were diabetics. None of
our patients were positive for HIV or had been treated with
immunosuppressive therapy. The mean PD experience prior to FP
was 53 months (range 0–168 months). Six patients (67%) had been
treated with antibiotics in the previous 3 months for bacterial
peritonitis; none of them had received antifungal prophylaxis. One
episode was associated with appendicitis. The mean dialysate
white cell count was 7.74  109/l (range 0.06–39.3  109/l).
All episodes of FP were caused by Candida species. Only one
episode was caused by C. albicans. Among the other eight episodes,
three were caused by C. parapsilosis, three by Candida tropicalis, oneby C. krusei, and one by C. glabrata (Table 1). Gram staining of the
peritoneal ﬂuid showed yeasts in seven patients; the mean time to
culture positivity was 3.75 days.
Comparative in vitro susceptibilities are summarized in Table 1.
Four of the nine isolates (two C. tropicalis, one C. albicans, and one C.
parapsilosis) were sensitive to all three classes of antifungal, i.e., the
polyene amphotericin B, triazoles, and the echinocandins. Three
isolates were resistant to amphotericin B, i.e., MIC = 2 mg/l (C.
tropicalis, C. parapsilosis, and C. glabrata). Of these three isolates, the
C. tropicalis isolate was also resistant to itraconazole (MIC = 1 mg/
l), and the C. glabrata isolate was resistant to both itraconazole
(MIC = 32 mg/l) and voriconazole (MIC = 32 mg/l), and intermedi-
ate to ﬂuconazole (MIC = 16 mg/l). The C. krusei isolate was
considered intrinsically resistant to ﬂuconazole. In general,
compared to the other Candida spp, the caspofungin and
micafungin MICs were higher with C. parapsilosis. One isolate
was highly resistant to micafungin (MIC = 16 mg/l).
Initial empirical antifungal therapy was as follows: ﬂuconazole
in six episodes, amphotericin B in two episodes, and caspofungin
in one episode. Resistance of the isolate to the initial antifungal
agent was associated with a switch to another appropriate agent
in three patients. All nine patients had the PD catheter surgically
removed after the diagnosis of FP, with a mean lag time between
diagnosis and removal of 7.6 days (range 2–13 days). The mean
total duration of antifungal treatment was 23.4 days. All patients
survived the episode, but only one patient resumed PD 12 months
later. One patient developed sclerosing peritonitis during the
initial hospitalization for FP and was treated successfully with
mycophenolate and prednisone. She was transferred permanently
to hemodialysis.7
4. Discussion
Fungal peritonitis is a relatively rare complication in patients on
PD. It represents only 3% to 6% of all episodes of peritonitis, but is
associated with much greater morbidity and mortality than
bacterial peritonitis.1 Initial empirical antifungal therapy has to
take into account the frequency of different species of fungi based
on the local epidemiology, and their susceptibilities to different
antifungal agents.
Although larger series of FP in PD have already been published
(Miles et al., 2009, 162 cases;3 Wang et al., 2000, 70 cases;8 Goldie
et al., 1996, 55 cases;9 Nagappan et al., 1992, 38 cases;10 Prasad
et al., 2004, 28 cases;11 Michel et al., 1994, 20 cases12), antifungal
susceptibility testing of isolates has been reported in only two
series. The ﬁrst series was from Mexico and reported antifungal
susceptibilities to triazoles only. Ten Candida isolates were
identiﬁed with various triazole resistance patterns.4 The other
series, from Greece, reported 46 episodes of fungal peritonitis.
Isolates were tested for susceptibility to amphotericin B and
various triazoles. Amphotericin B was the only antifungal agent to
which all recovered organisms were susceptible.5 No susceptibility
Table 2
Antifungal treatment before and after antibiotic susceptibility testing
Year Sex/age Species Empirical treatment Treatment after fungus identiﬁcation
1997 F/56 C. tropicalis Fluconazole Amphotericin B
1997 M/78 C. parapsilosis Fluconazole Amphotericin B
1997 M/35 C. tropicalis Fluconazole Fluconazole
1997 M/75 C. albicans Fluconazole Fluconazole
1998 M/69 C. parapsilosis Fluconazole Fluconazole
1999 M/67 C. krusei Fluconazole Amphotericin B
2001 F/62 C. parapsilosis Amphotericin B Fluconazole
2002 M/51 C. glabrata Amphotericin B Caspofungin
2003 M/61 C. tropicalis Caspofungin Fluconazole
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have been published for the PD population. Our study is also the
ﬁrst series of FP in PD patients reported from Canada.
All nine cases of FP reported in this study were caused by
Candida species. This appears somewhat different from the
literature where Candida species represent 68–90% of causative
organisms.3,8–12 This may be explained by larger series and
different geographical areas. In our series, only one case of
peritonitis was caused by C. albicans. This is in accordance with the
literature where the majority (from 50% to 80%) of Candida species
isolated are non-albicans Candida species.3,8–12 As described in all
other series, C. parapsilosis and C. tropicalis were the most frequent
Candida species.
Variable in vitro susceptibility patterns were observed in our
isolates. Low resistance rates to ﬂuconazole, itraconazole, and
voriconazole have been reported in our institution for Candida
bloodstream infection isolates.13 Not surprisingly similar observa-
tions were noted with our peritoneal ﬂuid Candida spp isolates.
Fluconazole resistance was predictable with C. krusei, and resistance
to itraconazole and voriconazole was not unexpected with our C.
glabrata isolate. Resistance to speciﬁc triazoles has also been
described in the literature with some isolates of C. albicans, C.
parapsilosis, and C. tropicalis. Of concern was the amphotericin B MIC
of 2 mg/l observed in one C. tropicalis, one C. parapsilosis, and one C.
glabrata isolate. This is the ﬁrst published report of in vitro resistance
of Candida spp isolates to amphotericin B in a PD population. One C.
parapsilosis was resistant to micafungin. Although all isolates
appeared sensitive to caspofungin, the echinocandin MICs were in
general higher against C. parapsilosis. The clinical signiﬁcance of such
observations remains to be determined.6,14 It however underscores
the importance of individual speciation and susceptibility testing of
invasive Candida isolates. Combination therapy with amphotericin B
and ﬂuconazole as initial empirical therapy may be appropriate until
speciation of the Candida isolate in the peritoneal ﬂuid is
established.
Two-thirds of our patients had received antibiotics within the
previous 3 months, a well-known risk factor for FP in PD
patients.1,3,9,15 All patients survived in our study, in contrast to
a reported lethality of FP of between 5% and 50%.2 The reason for
this is probably multifactorial, including the relatively small
number of cases in this study, the absence of fungus other than
Candida in our series, and the fact that all patients had their
catheter removed, which has been shown to reduce mortality in
previous studies.2,3 Finally, access to antifungal susceptibility
proﬁles may have helped to optimize the treatment and outcome
of our patients (Table 2).
One of our patients presented a sclerosing peritonitis during the
initial hospitalization. Sclerosing peritonitis is another rare and
frequently lethal complication in patients on PD, characterized by
ﬁbrosis of the visceral and parietal peritoneum.16 This patient
experienced a favorable outcome with cessation of PD and
immunosuppressive therapy.7 Previous peritonitis, either bacterial
of fungal, may predispose to sclerosing peritonitis.16,17In conclusion, fungal peritonitis is a rare complication of PD that
is associated with signiﬁcant morbidity and mortality. In our center,
during a 10-year period, nine cases of fungal peritonitis were found
among 288 PD patients, and all cases were caused by Candida
species, with a majority of non-albicans Candida species. Resistance
to ﬂuconazole was rare, and potential resistance to amphotericin B
was observed in one-third of the isolates recovered in this small
series. The echinocandins were less active in vitro against the C.
parapsilosis isolates. These observations must be taken into
consideration when choosing the most appropriate initial empirical
antifungal therapy. Deﬁnitive treatment is based on susceptibility
testing results and cost-effectiveness considerations.
Conﬂict of interest: No conﬂict of interest to declare.
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